* Fulcrum Therapeutics Inc reported a quarterly adjusted loss of 35 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of nine analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -47 cents to -37 cents per share.
* Reported revenue was zero; analysts expected zero.
* Fulcrum Therapeutics Inc's reported EPS for the quarter was a loss of 35 cents.
* The company reported a quarterly loss of $21.7 million.
* Fulcrum Therapeutics Inc shares had risen by 2.0% this quarter and lost 46.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00 This summary was machine generated from LSEG data November 13 at 03:25 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.41 -0.35 Beat
Jun. 30 2024 -0.01 0.87 Beat
Mar. 31 2024 -0.44 -0.43 Beat
Dec. 31 2023 -0.43 -0.40 Beat
Comments